Allogeneic heart valve storage above the glass transition at -80°C.

Ann Thorac Surg

Cell & Tissue Systems, Inc, North Charleston, South Carolina 29406, USA.

Published: June 2011

Background: Cryopreserved allogeneic heart valves are usually stored and transported below -135°C; however, such methods require expensive equipment for both storage and transportation.

Methods: In this study, vitrified porcine aortic valves were stored on either side of the cryoprotectant formulation's glass transition temperature (-119°C) at -80°C and -135°C, using a newly formulated vitrification solution (VS83) consisting of a combination of 4.65M dimethyl sulfoxide, 4.65M formamide, and 3.30M 1,2-propanediol. Three groups of valves were studied: (1) fresh; (2) VS83-preserved, stored at -80°C; and (3) VS83-preserved, stored at -135°C.

Results: Using the VS83 cryoprotectant concentration formulation, cracking was not observed during valve storage. No ice-related events were detectable during 5°C rewarming by differential scanning calorimetry. All cryopreserved tissue samples demonstrated significantly less viability than fresh samples (p<0.01). No significant viability differences were observed between the VS83-preserved groups stored at -80°C and -135°C. Material testing did not reveal any significant differences among the three test groups. Multiphoton imaging of VS83-preserved heart valves stored at -80°C and -135°C demonstrated similar collagen and elastin structures.

Conclusions: These results indicate that VS83-preserved heart valves can be stored and transported at temperatures in the vicinity of -80°C with retention of extracellular matrix integrity and material properties. The VS83 preservation of heart valves at -80°C without the need for liquid nitrogen should result in both decreased manufacturing costs and reduced employee safety hazards. Moreover, it is anticipated that low cell viability may result in less immunogenicity in vivo.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2011.02.043DOI Listing

Publication Analysis

Top Keywords

allogeneic heart
8
valve storage
8
glass transition
8
valves stored
8
vs83-preserved stored
8
heart valve
4
storage glass
4
transition -80°c
4
-80°c background
4
background cryopreserved
4

Similar Publications

Acute lymphoblastic leukemia (ALL) is a malignant condition of lymphoid progenitor cells that primarily affects the pediatric population, but also adults. The 5-year survival rate is 90% in children and approximately 40% in adults, with survival increasing through the use of peripheral stem cell allotransplantation (SCT). The relapse rate after stem cell transplantation (SCT) in adult acute lymphoblastic leukemia (ALL) patients ranges from 35% to 45%, making relapse a major cause of death in this population.

View Article and Find Full Text PDF

Tannic acid-modified FK506-loaded nanoparticles targeting lymph nodes for acute heart transplant rejection treatment.

Int J Pharm

January 2025

Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022 China; Clinical Research Center for Medical Imaging in Hubei Province, Wuhan 430022 China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022 China. Electronic address:

Significant efforts have been made to deliver immunosuppressants-loaded nanoparticles (NPs) to lymph nodes (LNs) to mitigate transplant rejection. However, conventional administration techniques encounter challenges in enhancing the retention of NPs in the LNs. Attributing the strong affinity of tannic acid (TA) molecules to the elastin of LN conduits, we developed a novel formulation of NPs encapsulating Tacrolimus (FK506), and subsequently modified with TA to produce TA-FNP with a final diameter of approximately 86.

View Article and Find Full Text PDF

Evaluating Safety and Outcomes of Living Allogenic Heart Valve Transplantation: The Case for a Multicenter Prospective Clinical Registry.

J Thorac Cardiovasc Surg

January 2025

Section of Congenital and Pediatric Cardiac Surgery, Division of Cardiac, Thoracic, and Vascular Surgery, NY-Presbyterian Morgan Stanley Children's Hospital, Columbia University Medical Center, New York, NY, USA. Electronic address:

View Article and Find Full Text PDF

Background: Immune effector cell (IEC) therapies, including chimeric antigen receptor (CAR)-modified T-cell therapy, have shown efficacy in pediatric B-cell acute lymphoblastic leukemia (B-ALL) and are being investigated for other malignancies. A common toxicity associated with IEC therapy is cytokine release syndrome (CRS), which can lead to cardiovascular decompensation due to systemic inflammation. Data are limited regarding cardiovascular adverse effects in children.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!